First-line treatment for nausea and vomiting of pregnancy, alone or in combination with doxylamine (Diclegis/Bonjesta — the only FDA-approved pharmacotherapy for NVP). Also essential for fetal neurological development and amino acid metabolism. No teratogenicity at standard doses. High doses (>100 mg/day chronically) can cause peripheral neuropathy in the mother.
How it works
Mechanism information is still being processed. Check the DailyMed link in the sidebar for the official prescribing information.
Dosing & administration
Dosing varies by indication and patient profile. Always follow your institution's current prescribing guidelines.
Renal impairment
Consult protocols for adjustment.
Liver impairment
Consult protocols for adjustment.
Use during pregnancy
1st trimester
Safe. First-line antiemetic for NVP. Standard dose 10–25 mg three to four times daily.
2nd trimester
Safe.
3rd trimester
Safe.
Clinical note
First-line treatment for nausea and vomiting of pregnancy, alone or in combination with doxylamine (Diclegis/Bonjesta — the only FDA-approved pharmacotherapy for NVP). Also essential for fetal neurological development and amino acid metabolism. No teratogenicity at standard doses. High doses (>100 mg/day chronically) can cause peripheral neuropathy in the mother.
Breastfeeding
Safe. Essential vitamin; present in breast milk naturally.
Warnings & precautions
When not to use it
Avoid in patients with known hypersensitivity to this drug or any of its components.
Drug interactions
Loading safety data…
Pyridoxine (Vitamin B6) | Drug Overview & Clinical Reference
